Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perampanel monotherapy in untreated partial-onset seizures
2019-003734-17Phase 3
- Sponsor
- Eisai Co., Ltd.
- Start
- Nov 2019
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of perampanel in epilepsy and Focal onset seizure, sponsored by Eisai Co., Ltd. Primary endpoint: Seizure-free rate during the 26-week maintenance period.
02
Drugs
perampanel
03
Conditions
epilepsyFocal onset seizure
Beyond the preview
Go deeper on 2019-003734-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003734-17.